BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11098489)

  • 1. Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
    Bastian G; Seitz JF; Moutardier V; Delperro JR; Fargeot P; Fraisse J; Formento P; Chazard M; Renée N; Milano G
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):35-7. PubMed ID: 11098489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
    Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
    Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
    Yano A; Hashimoto K; Okuchi T; Mizoguchi H; Mutaguchi K; Nakamoto T; Usui T
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1877-83. PubMed ID: 11729480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat].
    Mitsuishi K; Umeno T; Tanaka S; Kimura H; Fuchino Y; Tomita A; Ikeda S
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1119-24. PubMed ID: 9239165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
    Miyamoto H; Morio A; Izumi H; Yamazaki A; Wang Z; Futagawa T; Sonobe S
    Anticancer Res; 2003; 23(5b):4153-6. PubMed ID: 14666617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].
    Funahashi K; Koike J; Saito N; Miki T; Matsumoto H; Ryu M; Shiokawa H; Tokuyama T; Goto T; Teramoto T
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):189-93. PubMed ID: 14997749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
    Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
    Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
    Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UFT in the treatment of colorectal and breast cancer.
    Sun W; Haller D
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
    Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
    Jakobsen A
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):32-4. PubMed ID: 11098488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Noel D; Sonnichsen DS; Birkhofer MJ
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):22-5. PubMed ID: 9348562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.